AROG Pharmaceuticals
Pre-clinicalPhase III-ready FLT3 inhibitor for post-allogeneic HSCT maintenance in high-risk AML. Over 400 patients treated.
Founded
2017
Focus
Small Molecules
About
Phase III-ready FLT3 inhibitor for post-allogeneic HSCT maintenance in high-risk AML. Over 400 patients treated.
Funding History
4Total raised: $115M
Series B$50MUndisclosedMar 15, 2021
Series A$25MUndisclosedJun 15, 2019
Series B$25MUndisclosedJun 15, 2009
Series A$15MUndisclosedJun 15, 2007
Company Info
TypePrivate
Founded2017
LocationDallas, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile